IDH1/2 mutations confer a gain of function in glioma cells, resulting in the accumulation and secretion of a vast excess of an oncometabolite, D-2-HG, which ultimately inhibits the catalytic activity of α-KG-dependent dioxygenase, damaging the key steps in histone modification and DNA demethylation (21). This evidence concerns the gene IDH1 and glioma.